{
    "2018-10-09": [
        [
            {
                "time": "2018-10-09",
                "original_text": "Novartis Announces Positive Sickle-cell Pain Trial",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Positive",
                        "Sickle-cell",
                        "Pain",
                        "Trial"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-09",
                "original_text": "Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study",
                "features": {
                    "keywords": [
                        "Novartis",
                        "crizanlizumab",
                        "SEG101",
                        "patients",
                        "sickle cell",
                        "pain crises",
                        "placebo",
                        "SUSTAIN study"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-09",
                "original_text": "Considering Novartis’s Revenue Growth Rate",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Revenue",
                        "Growth",
                        "Rate"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-09",
                "original_text": "How Artificial Intelligence Is Helping Pharmaceuticals Develop Drugs",
                "features": {
                    "keywords": [
                        "Artificial Intelligence",
                        "Pharmaceuticals",
                        "Develop",
                        "Drugs"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "technology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-09",
                "original_text": "A Look at Novartis’s Valuation on October 9",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Valuation"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-09",
                "original_text": "Assessing Novartis’s Performance in October So Far",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Performance",
                        "October"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-09",
                "original_text": "In a small San Francisco office, Big Pharma zeroes in on digital health",
                "features": {
                    "keywords": [
                        "Big Pharma",
                        "digital health",
                        "San Francisco"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "technology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-09",
                "original_text": "Pre-Market Most Active for Oct 9, 2018: QQQ, PYX, NVS, GE, SQQQ, BABA, TVIX, SNAP, DB, ERIC, TLT, AFMD",
                "features": {
                    "keywords": [
                        "Pre-Market",
                        "Most Active",
                        "Oct 9",
                        "QQQ",
                        "PYX",
                        "NVS",
                        "GE",
                        "SQQQ",
                        "BABA",
                        "TVIX",
                        "SNAP",
                        "DB",
                        "ERIC",
                        "TLT",
                        "AFMD"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "market",
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-09",
                "original_text": "Ionis Pharmaceuticals: Recent Developments and Analysts’ Ratings",
                "features": {
                    "keywords": [
                        "Ionis Pharmaceuticals",
                        "Recent Developments",
                        "Analysts’ Ratings"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}